Mazisotine not checked
Eli Lilly · LY3556050 · CNTX-0290
FollowEvery change as it happens, and a Monday email
Trials
1 active
8 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.”In the company’s words, NCT05986292 on ClinicalTrials.gov
- Other names
- LY3556050 · CNTX-0290
Other drugs for Osteoarthritis, Knee
- JointstemR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up1
- Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Apr 2027 | A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | |
| Phase 2Completed | 21 Oct 2021 | Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis | |
| Phase 2Completed | 9 Feb 2022 | Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain | |
| Phase 2Terminated | 13 Jun 2022 | Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain | |
| Phase 2Completed | 11 Jun 2025 | A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain | |
| Phase 1Completed | 2 Jun 2017 | A Study of Single and Repeated Doses of LY3556050 in Healthy Participants | |
| Phase 1Completed | 27 Dec 2022 | A Study of Effect of LY3556050 on Metformin in Healthy Participants | |
| Phase 1Completed | 4 Nov 2023 | A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026